Download PDF
Semin Liver Dis 2015; 35(03): 291-303
DOI: 10.1055/s-0035-1562948
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease

Laurent Castera
1   Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-VII, Clichy, France
› Author Affiliations
Further Information

Publication History

Publication Date:
17 September 2015 (online)

    Permissions and Reprints

Abstract

Key issues in patients with nonalcoholic fatty liver disease (NAFLD) are the differentiation of nonalcoholic steatohepatitis (NASH) from simple steatosis and staging of liver fibrosis, as patients with NASH/advanced fibrosis are at greatest risk of developing complications of end-stage liver disease. The controlled attenuation parameter is the most promising noninvasive technique for detecting and quantifying hepatic steatosis, but needs to be implemented with the XL probe and compared with ultrasound that, despite its limitations, remains the most widely used method. Cytokeratin-18 is currently the most extensively validated serum marker of NASH as a stand-alone test or as part of prediction models. However, it is not widely available and thus has not been introduced yet into practice. Transient elastography, as well as FIB-4 and NAFLD fibrosis scores are the best methods to rule out severe fibrosis and cirrhosis. However, the high rate of unreliable results with transient elastography remains a challenge, which is not completely addressed by the use of the XL probe. Given the high prevalence of NAFLD in the general population, these noninvasive methods could be used in clinical practice as first-line tools to screen patients with NAFLD to help determine those who may still require a liver biopsy.

Keywords

nonalcoholic fatty liver disease - noninvasive - steatosis - nonalcoholic steatohepatitis - fibrosis - serum markers - transient elastography
 

  • References

  • 1 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16) 1221-1231
    CrossrefPubMedGoogle Scholar
  • 2 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344 (7) 495-500
    CrossrefPubMedGoogle Scholar
  • 3 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25 (2) 291-303
    PubMedGoogle Scholar
  • 4 Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready?. Lancet 2010; 375 (9724) 1419-1420
    CrossrefPubMedGoogle Scholar
  • 5 Poynard T, Ratziu V, Naveau S , et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10
    CrossrefPubMedGoogle Scholar
  • 6 Poynard T, Lassailly G, Diaz E , et al; FLIP consortium. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7 (3) e30325
    CrossrefPubMedGoogle Scholar
  • 7 Bedogni G, Bellentani S, Miglioli L , et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
    CrossrefPubMedGoogle Scholar
  • 8 Kotronen A, Peltonen M, Hakkarainen A , et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137 (3) 865-872
    CrossrefPubMedGoogle Scholar
  • 9 Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010; 10: 98
    CrossrefPubMedGoogle Scholar
  • 10 Lee JH, Kim D, Kim HJ , et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42 (7) 503-508
    CrossrefPubMedGoogle Scholar
  • 11 Calori G, Lattuada G, Ragogna F , et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54 (1) 145-152
    CrossrefPubMedGoogle Scholar
  • 12 Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V ; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40 (10) 1209-1222
    CrossrefPubMedGoogle Scholar
  • 13 Kahl S, Straßburger K, Nowotny B , et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS ONE 2014; 9 (4) e94059
    CrossrefPubMedGoogle Scholar
  • 14 Sasso M, Beaugrand M, de Ledinghen V , et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36 (11) 1825-1835
    CrossrefPubMedGoogle Scholar
  • 15 de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32 (6) 911-918
    CrossrefPubMedGoogle Scholar
  • 16 Myers RP, Pollett A, Kirsch R , et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32 (6) 902-910
    CrossrefPubMedGoogle Scholar
  • 17 Sasso M, Tengher-Barna I, Ziol M , et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012; 19 (4) 244-253
    CrossrefPubMedGoogle Scholar
  • 18 Friedrich-Rust M, Romen D, Vermehren J , et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81 (3) e325-e331
    CrossrefPubMedGoogle Scholar
  • 19 Masaki K, Takaki S, Hyogo H , et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res 2013; 43 (11) 1182-1189
    CrossrefPubMedGoogle Scholar
  • 20 Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29 (7) 1470-1476
    CrossrefPubMedGoogle Scholar
  • 21 Chon YE, Jung KS, Kim KJ , et al. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci 2015; 60 (1) 234-242
    CrossrefPubMedGoogle Scholar
  • 22 de Lédinghen V, Vergniol J, Capdepont M , et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014; 60 (5) 1026-1031
    CrossrefPubMedGoogle Scholar
  • 23 Ferraioli G, Tinelli C, Lissandrin R , et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 2014; 20 (21) 6626-6631
    CrossrefPubMedGoogle Scholar
  • 24 Kumar M, Rastogi A, Singh T , et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?. J Gastroenterol Hepatol 2013; 28 (7) 1194-1201
    CrossrefPubMedGoogle Scholar
  • 25 Mi YQ, Shi QY, Xu L , et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. Dig Dis Sci 2015; 60 (1) 243-251
    CrossrefPubMedGoogle Scholar
  • 26 Shen F, Zheng RD, Mi YQ , et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014; 20 (16) 4702-4711
    CrossrefPubMedGoogle Scholar
  • 27 Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20 (30) 10585-10590
    CrossrefPubMedGoogle Scholar
  • 28 Chon YE, Jung KS, Kim SU , et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014; 34 (1) 102-109
    CrossrefPubMedGoogle Scholar
  • 29 Jung KS, Kim BK, Kim SU , et al. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS ONE 2014; 9 (6) e98689
    CrossrefPubMedGoogle Scholar
  • 30 Shi KQ, Tang JZ, Zhu XL , et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29 (6) 1149-1158
    CrossrefPubMedGoogle Scholar
  • 31 Castéra L, Foucher J, Bernard PH , et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (3) 828-835
    PubMedGoogle Scholar
  • 32 Kwok R, Choi KC, Wong GL , et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2015; . In press
    PubMedGoogle Scholar
  • 33 Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol 2014; 60 (5) 910-912
    CrossrefPubMedGoogle Scholar
  • 34 Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2014; 34 (6) e111-e117
    CrossrefPubMedGoogle Scholar
  • 35 Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol 2013; 25 (11) 1330-1334
    CrossrefPubMedGoogle Scholar
  • 36 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53 (2) 372-384
    CrossrefPubMedGoogle Scholar
  • 37 Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44 (1) 27-33
    CrossrefPubMedGoogle Scholar
  • 38 Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50 (4) 1072-1078
    CrossrefPubMedGoogle Scholar
  • 39 Diab DL, Yerian L, Schauer P , et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008; 6 (11) 1249-1254
    CrossrefPubMedGoogle Scholar
  • 40 Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol 2012; 63 (4) 347-353
    PubMedGoogle Scholar
  • 41 Joka D, Wahl K, Moeller S , et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012; 55 (2) 455-464
    CrossrefPubMedGoogle Scholar
  • 42 Musso G, Cassader M, De Michieli F, Saba F, Bo S, Gambino R. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011; 94 (4) 1033-1042
    CrossrefPubMedGoogle Scholar
  • 43 Papatheodoridis GV, Hadziyannis E, Tsochatzis E , et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol 2010; 44 (4) e87-e95
    CrossrefPubMedGoogle Scholar
  • 44 Pirvulescu I, Gheorghe L, Csiki I , et al. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery. Chirurgia (Bucur) 2012; 107 (6) 772-779
    PubMedGoogle Scholar
  • 45 Yilmaz Y, Dolar E, Ulukaya E , et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13 (6) 837-844
    CrossrefPubMedGoogle Scholar
  • 46 Younossi ZM, Jarrar M, Nugent C , et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18 (11) 1430-1437
    CrossrefPubMedGoogle Scholar
  • 47 Shen J, Chan HL, Wong GL , et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012; 56 (6) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 48 Cusi K, Chang Z, Harrison S , et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014; 60 (1) 167-174
    CrossrefPubMedGoogle Scholar
  • 49 Kwok R, Tse YK, Wong GL , et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39 (3) 254-269
    CrossrefPubMedGoogle Scholar
  • 50 Poynard T, Ratziu V, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
    CrossrefPubMedGoogle Scholar
  • 51 Younossi ZM, Page S, Rafiq N , et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21 (4) 431-439
    CrossrefPubMedGoogle Scholar
  • 52 Anty R, Iannelli A, Patouraux S , et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32 (11-12) 1315-1322
    CrossrefPubMedGoogle Scholar
  • 53 Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121 (1) 91-100
    CrossrefPubMedGoogle Scholar
  • 54 Feldstein AE, Lopez R, Tamimi TA , et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 51 (10) 3046-3054
    CrossrefPubMedGoogle Scholar
  • 55 Hyysalo J, Männistö VT, Zhou Y , et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014; 60 (4) 839-846
    CrossrefPubMedGoogle Scholar
  • 56 Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006; 26 (2) 151-156
    CrossrefPubMedGoogle Scholar
  • 57 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58 (5) 1007-1019
    CrossrefPubMedGoogle Scholar
  • 58 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nature reviews. Gastroenterol Hepatol 2013; 10: 666-675
    PubMedGoogle Scholar
  • 59 Angulo P, Hui JM, Marchesini G , et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45 (4) 846-854
    CrossrefPubMedGoogle Scholar
  • 60 Qureshi K, Clements RH, Abrams GA. The utility of the “NAFLD fibrosis score” in morbidly obese subjects with NAFLD. Obes Surg 2008; 18 (3) 264-270
    CrossrefPubMedGoogle Scholar
  • 61 Wong VW, Wong GL, Chim AM , et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103 (7) 1682-1688
    PubMedGoogle Scholar
  • 62 Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57 (10) 1441-1447
    CrossrefPubMedGoogle Scholar
  • 63 Raszeja-Wyszomirska J, Szymanik B, Ławniczak M , et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010; 10: 67
    CrossrefPubMedGoogle Scholar
  • 64 Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 (6) 1356-1362
    CrossrefPubMedGoogle Scholar
  • 65 Kruger FC, Daniels CR, Kidd M , et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011; 101 (7) 477-480
    PubMedGoogle Scholar
  • 66 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7 (10) 1104-1112
    CrossrefPubMedGoogle Scholar
  • 67 Sumida Y, Yoneda M, Hyogo H , et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2
    CrossrefPubMedGoogle Scholar
  • 68 Ratziu V, Massard J, Charlotte F , et al; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6
    CrossrefPubMedGoogle Scholar
  • 69 Calès P, Lainé F, Boursier J , et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50 (1) 165-173
    PubMedGoogle Scholar
  • 70 Calès P, Oberti F, Michalak S , et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42 (6) 1373-1381
    CrossrefPubMedGoogle Scholar
  • 71 Adams LA, George J, Bugianesi E , et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26 (10) 1536-1543
    CrossrefPubMedGoogle Scholar
  • 72 Adams LA, Bulsara M, Rossi E , et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51 (10) 1867-1873
    CrossrefPubMedGoogle Scholar
  • 73 Rosenberg WM, Voelker M, Thiel R , et al; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127 (6) 1704-1713
    CrossrefPubMedGoogle Scholar
  • 74 Guha IN, Parkes J, Roderick P , et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47 (2) 455-460
    CrossrefPubMedGoogle Scholar
  • 75 Nobili V, Parkes J, Bottazzo G , et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009; 136 (1) 160-167
    CrossrefPubMedGoogle Scholar
  • 76 EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63 (1) 237-264
    CrossrefPubMedGoogle Scholar
  • 77 Sandrin L, Fourquet B, Hasquenoph JM , et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29 (12) 1705-1713
    CrossrefPubMedGoogle Scholar
  • 78 Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48 (4) 606-613
    CrossrefPubMedGoogle Scholar
  • 79 Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48 (5) 835-847
    CrossrefPubMedGoogle Scholar
  • 80 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142 (6) 1293-1302.e4
    CrossrefPubMedGoogle Scholar
  • 81 Yoneda M, Yoneda M, Mawatari H , et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40 (5) 371-378
    CrossrefPubMedGoogle Scholar
  • 82 Nobili V, Vizzutti F, Arena U , et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48 (2) 442-448
    CrossrefPubMedGoogle Scholar
  • 83 Wong VW, Vergniol J, Wong GL , et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51 (2) 454-462
    CrossrefPubMedGoogle Scholar
  • 84 Lupsor M, Badea R, Stefanescu H , et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19 (1) 53-60
    PubMedGoogle Scholar
  • 85 Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33 (12) 1350-1360
    CrossrefPubMedGoogle Scholar
  • 86 Gaia S, Carenzi S, Barilli AL , et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54 (1) 64-71
    CrossrefPubMedGoogle Scholar
  • 87 Myers RP, Pomier-Layrargues G, Kirsch R , et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55 (1) 199-208
    CrossrefPubMedGoogle Scholar
  • 88 Wong VW, Vergniol J, Wong GL , et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107 (12) 1862-1871
    CrossrefPubMedGoogle Scholar
  • 89 Naveau S, Lamouri K, Pourcher G , et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg 2014; 24 (10) 1693-1701
    CrossrefPubMedGoogle Scholar
  • 90 Kumar R, Rastogi A, Sharma MK , et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013; 58 (1) 265-274
    CrossrefPubMedGoogle Scholar
  • 91 Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299 (17) 926-930
    CrossrefPubMedGoogle Scholar
  • 92 Poynard T, Halfon P, Castera L , et al; FibroPaca Group. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53 (9) 1615-1622
    CrossrefPubMedGoogle Scholar
  • 93 Wong GL, Wong VW, Chim AM , et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011; 26 (2) 300-305
    CrossrefPubMedGoogle Scholar
  • 94 Friedrich-Rust M, Hadji-Hosseini H, Kriener S , et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol 2010; 20 (10) 2390-2396
    CrossrefPubMedGoogle Scholar
  • 95 de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010; 30 (7) 1043-1048
    CrossrefPubMedGoogle Scholar
  • 96 de Lédinghen V, Wong VW, Vergniol J , et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012; 56 (4) 833-839
    CrossrefPubMedGoogle Scholar
  • 97 Coco B, Oliveri F, Maina AM , et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14 (5) 360-369
    CrossrefPubMedGoogle Scholar
  • 98 Sagir A, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47 (2) 592-595
    CrossrefPubMedGoogle Scholar
  • 99 Arena U, Vizzutti F, Corti G , et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47 (2) 380-384
    CrossrefPubMedGoogle Scholar
  • 100 Millonig G, Reimann FM, Friedrich S , et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48 (5) 1718-1723
    CrossrefPubMedGoogle Scholar
  • 101 Millonig G, Friedrich S, Adolf S , et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52 (2) 206-210
    CrossrefPubMedGoogle Scholar
  • 102 Mederacke I, Wursthorn K, Kirschner J , et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009; 29 (10) 1500-1506
    CrossrefPubMedGoogle Scholar
  • 103 Arena U, Lupsor Platon M, Stasi C , et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013; 58 (1) 65-72
    PubMedGoogle Scholar
  • 104 Berzigotti A, De Gottardi A, Vukotic R , et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS ONE 2013; 8 (3) e58742
    CrossrefPubMedGoogle Scholar
  • 105 Boursier J, de Ledinghen V, Sturm N , et al; Multicentre group ANRS HC EP23 FIBROSTAR. Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. J Gastroenterol 2014; 49 (3) 527-537
    CrossrefPubMedGoogle Scholar
  • 106 Macaluso FS, Maida M, Cammà C , et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. J Hepatol 2014; 61 (3) 523-529
    CrossrefPubMedGoogle Scholar
  • 107 Arena U, Vizzutti F, Abraldes JG , et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57 (9) 1288-1293
    CrossrefPubMedGoogle Scholar
  • 108 Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation force impulse imaging: in vivo demonstration of clinical feasibility. Ultrasound Med Biol 2002; 28 (2) 227-235
    CrossrefPubMedGoogle Scholar
  • 109 Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound Med Biol 2013; 39 (11) 1942-1950
    CrossrefPubMedGoogle Scholar
  • 110 Palmeri ML, Wang MH, Rouze NC , et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55 (3) 666-672
    CrossrefPubMedGoogle Scholar
  • 111 Yoneda M, Suzuki K, Kato S , et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256 (2) 640-647
    CrossrefPubMedGoogle Scholar
  • 112 Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 59 (1) 180-182
    CrossrefPubMedGoogle Scholar
  • 113 Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995; 269 (5232) 1854-1857
    CrossrefPubMedGoogle Scholar
  • 114 Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47 (1) 332-342
    CrossrefPubMedGoogle Scholar
  • 115 Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268 (2) 411-419
    CrossrefPubMedGoogle Scholar
  • 116 Loomba R, Wolfson T, Ang B , et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60 (6) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 117 Cui J, Ang B, Haufe W , et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 2015; 41 (12) 1271-1280
    CrossrefPubMedGoogle Scholar
  • 118 Petta S, Vanni E, Bugianesi E , et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35 (5) 1566-1573
    CrossrefPubMedGoogle Scholar
  • 119 Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2) 191-198
    CrossrefPubMedGoogle Scholar
  • 120 Castéra L, Vergniol J, Foucher J , et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2) 343-350
    CrossrefPubMedGoogle Scholar
  • 121 Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut 2010; 59 (7) 861-866
    CrossrefPubMedGoogle Scholar
  • 122 Ngo Y, Munteanu M, Messous D , et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52 (10) 1887-1896
    CrossrefPubMedGoogle Scholar
  • 123 Naveau S, Gaudé G, Asnacios A , et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49 (1) 97-105
    CrossrefPubMedGoogle Scholar
  • 124 Parkes J, Roderick P, Harris S , et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59 (9) 1245-1251
    CrossrefPubMedGoogle Scholar
  • 125 Nunes D, Fleming C, Offner G , et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105 (6) 1346-1353
    CrossrefPubMedGoogle Scholar
  • 126 Vergniol J, Foucher J, Terrebonne E , et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140 (7) 1970-1979 , 1979.e1–1979.e3
    CrossrefPubMedGoogle Scholar
  • 127 Robic MA, Procopet B, Métivier S , et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011; 55 (5) 1017-1024
    CrossrefPubMedGoogle Scholar
  • 128 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57 (4) 1357-1365
    CrossrefPubMedGoogle Scholar
  • 129 Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19 (8) 1219-1229
    CrossrefPubMedGoogle Scholar